Brivaracetam UCB

Current Opinion in Investigational Drugs

Volumn 6, Issue 7, 2005, Pages 740-746

  Malawska, Barbara ^a   Kulig, Katarzyna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BRIVARACETAM; CALCIUM ION; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; GABAPENTIN; PHENYTOIN; PRIMIDONE; PROPRANOLOL; SODIUM ION; UCB 100406 1; UCB 42145; UNCLASSIFIED DRUG; VALPROIC ACID;

AGITATION; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; CALCIUM CURRENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; ESSENTIAL TREMOR; EUPHORIA; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; MAXIMUM TOLERATED DOSE; MOOD DISORDER; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; REVIEW; SEDATION; SIDE EFFECT; SODIUM CURRENT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; THROAT DISEASE; VISUAL IMPAIRMENT; XEROSTOMIA;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; EPILEPSY; HUMANS; MOLECULAR STRUCTURE; NEURALGIA; PYRROLIDINONES;

EID: 21344472567     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. 434789 UCB initiates clinical trials with new innovative drug compound intended for the treatment of neurological disorders. UCB Pharma SA PRESS RELEASE 2001 November 13
2. 463402 Synthesis of newer KEPPRA analogs. Archen L, Differding E, Evrard Y, Frycia A, Gotteaux C, Fulks B, Gillard M, Kenda B, Klitgaard H, Lallemand B, Matagne A et al DRUGS FUTURE 2002 27 Suppl A P379
3. 513519 UCB 34714, a new pyrrolidone derivative, is effective in two models of human neuropathy in the rat: Comparison to gabapentin. Lamberly Y, Ardid D, Eschalier A, Allow A, Segal JA, Matagne A, Kenda B, Michel P, Klitgaard HV ABSTR SOC NEUROSCI 2003 33 Abs 586.8
4. 513520 UCB 34714, a new pyrrolidone derivative, reveals potent activity in in vitro and in vivo models of epilepsy. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard HV ABSTR SOC NEUROSCI 2003 33 Abs 634.19
5. 513521 UCB 34714, a new pyrrolidone derivative, antagonizes harmaline-induced tremor in rats: Comparison to drugs for essential tremor and anti-epileptic drugs. De Ryck M, Matagne A, Kenda B, Michel P, Klitgaard HV ABSTR SOC NEUROSCI 2003 33 Abs 634.20
6. 514511 Society for Neuroscience - 33rd Annual Meeting (Part XI), New Orleans, LA, USA. Taylor DP IDDB MEETING REPORT 2003 November 8-12
7. 517569 UCB: Confidence in the future - significant programmes for R&D. UCB SA PRESS RELEASE 2003 December 18
8. 518203 American Epilepsy Society - 57th Annual Meeting, Boston, MA, USA. Pitkanen A IDDB MEETING REPORT 2003 December 05-10
9. 526723 Early identification of refractory epilepsy. Kwan P, Brodie MJ N ENGL J MED 2000 342 5 314-319
10. 540000 New antiepileptic drugs - Seventh Eilat Conference, Sardinia, Italy. Pitkanen A IDDB MEETING REPORT 2004 May 09-13
11. 544763 Epileptology - Sixth European Congress, Vienna, Austria. Pitkanen A IDDB MEETING REPOPT 2004 May 30 - June 03
12. 548202 Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P J MED CHEM 2004 47 3 530-549
13. 553128 Discovery of UCB 34714 : A new pyrrolidone derivative with antiepileptic properties. INT SYMP MED CHEM 2004 18 Abs 5B
14. 574228 UCB announces positive new products results. UCB SA PRESS RELEASE 2004 December 02
15. 576835 American Epilepsy Society - 58th Annual Meeting, Novel Compounds for the Treatment of Seizures, New Orleans, LA, USA. Pitkanen A IDDB MEETING REPORT 2004 December 03-07
16. 583827 UCB 34714, a new pyrrolidone anticonvulsant, had no effect on voltage-gated potassium currents in cultured mouse hippocampal neurons. Margineanu DG, Schlobohm I, Klitgaard H EPILEPSIA 2004 45 3 116
17. 583828 UCB 34714: Effect on inhibitory and excitatory neurotransmission. Rigo JM, Nguyen L, Hans G, Belachew S, Moonen G, Matagne A, Klitgaard H EPILEPSIA 2004 45 3 56
18. 583836 Progress report on new antiepiletic drugs: A summary of the seventh Eilat Conference (EILAT VII). Bialer M, Johannessen SI, Kupferberg H, Levy RH, Perucca E, Tomson T EPILEPSY RES 2004 61 1-3 1-48
19. 583861 UCB 34714, a new pyrrolidone derivative: Comparison with levetiracetam in hippocampal slice epilepsy models in vitro. Margineanu DG, Kenda B, Michel P, Matagne A, Klitgaard H EPILEPSIA 2003 44 Suppl 9 Abs 2.246
20. 583864 UCB 34714, a new pyrrolidone derivative: Comparison with levetiracetam in animal models of chronic epilepsy in vivo. Matagne A, Kenda B, Michel P, Klitgaard H EPILEPSIA 2003 44 9 Abs 2.245
21. 583865 UCB 34714, a new pyrrolidone derivative inhibits epileptiform responses in hippocampal slices in vitro. Margineanu DG, Kenda B, Michel P, Matagne A, Klitgaard H EPILEPSIA 2003 44 Suppl 8 Abs P551
22. 583866 UCB 34714, a new pyrrolidine derivative suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo. Matagne A, Kenda B, Michel P, Klitgaard H EPILEPSIA 2003 44 Suppl 8 Abs 072
23. 593746 Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Klitgaard H EPILEPSIA 2001 42 Suppl 4 13-18
24. 593750 Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Margineanu DG, Klitgaard H PHARMACOL RES 2000 42 4 281-285
25. 593752 Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Klitgaard H, Matagne A, Gobert J, Wulfert E EUR J PHARMACOL 1998 353 2-3 191-206
26. 593753 The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B PROC NATL ACAD SCI USA 2004 101 26 9861-9866
27. 599783 UCB 34714, a new pyrrolidone derivative without impact on high-and low-voltage activated calcium currents in rat isolated neurons. Kostyuk PG, Lukyanetz EA, Klitgaard H, Margineanu DG EPILEPSIA 2004 45 Suppl 7 Abs 1.375
28. + currents in rat cortical neurons in culture. Zona C, Pieri M, Klitgaard H, Margineanu DG EPILEPSIA 2004 45 Suppl 7 Abs 1.388
29. 599790 Proof of principle in the new AED UCB 34714: Use of the photosensitivity model. Kasteleijn-Nolst Trenite DG, Parain D, Masnou P, Genton P, Steinhoff BJ, Hirsch E EPILEPSIA 2004 45 Suppl 7 Abs 2.349
30. 599791 UCB 34714: Single and multiple rising dose safety tolerability and pharmacokinetics in healthy subjects. Rolan P, Pigeolet E, Stockis A EPILEPSIA 2004 45 Suppl 7 Abs 2.365
31. 600429 Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. Loscher W, Potschka H J PHAPMACOL EXP THER 2002 301 1 7-14
32. 600431 Current status and future directions in the pharmacotherapy of epilepsy. Loscher W TRENDS PHARMACOL SCI 2002 23 3 113-118
33. 600433 The evaluation and treatment of seizures. Scheuer ML, Pedley TA N ENGL J MED 1990 323 21 1468-1474
34. 600434 The anti-epileptic drug levetiracetam reverses the inhibiton by negative allosteric modulators of neuronal GABA and glycine-gated currents. Rigo JM, Hans G, Nguyen L, Rocher L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H BR J PHARMACOL 2002 136 5 659-672
35. 600631 Pyrrolidone derivatives. Shorvon S LANCET 2001 358 9296 1885-1892
36. 602221 A new antiepileptic drug. Shorvon SD, van Rijckevorsel K J NEUROL NEUROSURG PSYCHIATRY 2002 72 4 426-429